Rational Use of Key Monitored Drugs Influenced by a Comprehensive Evaluation System for Clinical Medicine Based on Multidisciplinary Collaboration

doi:10.19803/j.1672-8629.2021.12.15

Abstract

Abstract: Objective To explore the applicability of the evaluation standard system for clinical rational drug use based on multi-disciplinary collaboration in enhancing the management of key monitored drugs.Methods Based on the multi-disciplinary collaboration model, an evaluation standard system for clinical rational drug use was established before drugs in the catalogue of key monitored drugs were traced throughout the hospital. The data on eight drugs in the first batch of the national key monitored drug catalogue was collected, while the changes of the irrational drug use rate were statistically analyzed. The interrupted time series (ITS) model was used to analyze the changes of adverse reactions,dosage and amount of these eight drugs before and after monitoring. At the same time, the changes of dosage and amount of four types of drugs of the first batch of key monitored drugs in the national catalogue (but not in the catalogue of key monitored drugs for our hospital) before and after monitoring were also statistically analyzed. Results Since the key drugs were monitored in September 2018, the rate of irrational use of eight types of drugs included in the key monitored catalogue of our hospital trended down (P<0.01). Nine months into monitoring of key drugs, the rate of irrational use of drugs remained less than 10%. The incidence of irrational clinical use of the eight types of drugs, irrational drug use, improper usage and dosage and failure to comply with the instructions was significantly lower in June 2019 than in September 2018 (P<0.01 or P<0.05). The number of ADR reports and incidence of ADRs before and after the monitoring of key drugs were not significantly different. After monitoring of key drugs, the amount of these eight types of drugs used (β₃=-3.79, P<0.01), and the amount of money (β₃=-4.256, P<0.01) involved decreased significantly, unlike the four types of drugs not included in the catalogue of key monitored drugs in our hospital.Conclusion The evaluation standard system for clinical rational use of drugs based on the multi-disciplinary collaboration model can effectively promote the clinical rational use of key monitored drugs..It is an effective model that should be popularized.

Key words: key monitoring drug, rational drug use, multidisciplinary collaboration, evaluation standard system, interrupted time series analysis, adverse drug reaction

CLC Number:

R994.11

ZHANG Wen, PENG Jing, CHEN Ju, LIU Jun, YANG Chunyan, WANG Peipei, YANG Xiaojun, YANG Kui, LIU Xiaoyun, ZHANG Haoran, ZHONG Zhengling, ZHAO Jun, TANG Zenghui, LUAN Jiajie. Rational Use of Key Monitored Drugs Influenced by a Comprehensive Evaluation System for Clinical Medicine Based on Multidisciplinary Collaboration[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1166-1170.

References

[1] General Office of the State Council. Guidelines on Improving the Centralized Procurement of Medicines in Public Hospitals.[EB/OL].(2015-02-28)[2019-12-01]. http://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm.
[2] General Office of the State Council. Some Opinions of the Leading Group of the State Council for Deepening the Reform of the Medical and Health Care System on Further Promoting and Deepening the Experience in the Reform of the Medical and Healthcare System[EB/OL].(2016-11-08)[2019-12-01]. http://www.gov.cn/xinwen/2016-11/08/content_5130271.htm.
[3] Medical Administration and Hospital Authority. Notice on the Issuance of the First Batch of State Key Monitoring and Rational Drug Use Catalogues (Chemical Drugs and Biological Products)[EB/OL].(2019-07-01)[2019-12-01].http://www.nhc.gov.cn/yzygj/s7659/201907/d356ce8a4ba1461ca66c544724dffc5e.shtml.
[4] Liang GK, Fu Y, Li JL, et al.Influence of key monitoring drugs policy on the change of adjuvant drugs in sample area[J]. Chin Pharm J(中国药学杂志), 2018, 53(18): 1613-1618.
[5] Li J, Wang ZC, Li J, et al.Optimize drug management through drug budgets under the new medical reform[J]. Clinical Medication Journal(临床药物治疗杂志), 2018, 16(11): 20-22.
[6] Sun MR, Wang LY, Qian CY, et al.Practice of management and control of rational adjuvant drug use in our hospital[J]. China Pharm(中国药房), 2018, 29(17): 2310-2314.
[7] National Health Commission. Notification on the Implementation Of Drug Use Monitoring and Comprehensive Clinical Evaluation[EB/OL].(2019-04-03)[2019-12-01]. http://cdsip.nhfpc.gov.cn/work/show18341.html.
[8] Zhao QG, Sun L.Application of multidisciplinary collaboration combined with clinical pharmacist intervention in adjuvant medication management[J]. J Community Med(社区医学杂志), 2018, 16(7): 79-80.
[9] Tang HL, Zhang T, Liu F, et al.An exploratory study on the method and process of evidence-based evaluation of off-label drug use[J]. Chin Pharm J(中国药学杂志), 2015, 50(19): 1735-1738.
[10] Zhang W, Wang L, Zhao YL, et al.Assessment of off-label use of alprostadil injection by evidence-based approach[J]. Chin J Hosp Pharm(中国医院药学杂志), 2017, 37(2): 177-180.
[11] Health and Family Planning Commission of Anhui Provinc. Notice of Anhui Province on improving the monitoring and early warning management system for key drugs in 2018[EB/OL].(2018-06-26)[2019-12-01]. http://www.chinaemed.com/Province/anhui/Docs/Policy/Policy/11911.
[12] Liang GK, Qin SB, Li JL, et al.Influence of key monitoring drugs policy on the change of proton pump inhibitors in sample areas[J]. Chin J Hosp Pharm(中国医院药学杂志), 2018, 38(22): 2299-2304.
[13] Chen LM, He XY, Huang JS, et al.Analysis of the effectiveness of the key monitoring and management of traditional Chinese medicine injections in one hospital[J]. J Guangdong Pharm Univ(广东药科大学学报), 2019, 35(1): 116-119.
[14] Xu Y, Xu WW, Li Y.Analysis of utilization of adjuvant drugs[J]. Chin J Hosp Pharm(中国医院药学杂志), 2017, 37(1): 73-75.
[15] Huang Q, Zhang Z, Liu LH.Analysis of 45 cases of adverse drug reaction induced by alprostadil[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(5): 304-308.
[16] Hu PZ, Ma L, Guo DH, et al.Automatic surveillance for hemoc-ytopenia caused by cinepazide maleate[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(12): 745-752.
[17] Zhang YY, Wu CF, Wu ZY, et al.Practice of adjuvant drugs control based on information platform[J]. Chinese Hospital Management(药事管理), 2018, 38(5): 54-55.
[18] Deng JX, Wang L, Chen WG, et al.Research and application of adverse drug reaction rapid reporting and intelligent searching system based on HIS[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(12): 731-734.